187 related articles for article (PubMed ID: 30285212)
1. Appendix 1: Cancer of the Prostate: eUpdate published online 28 September 2017 (http://www.esmo.org/Guidelines/Genitourinary-Cancers/Cancer-of-the-Prostate).
ESMO Guidelines Committee
Ann Oncol; 2018 Oct; 29(Suppl 4):iv256. PubMed ID: 30285212
[No Abstract] [Full Text] [Related]
2. Appendix 1: Renal cell carcinoma: MCBS eUpdate published online 10 April 2017(www.esmo.org/Guidelines/Genitourinary-Cancers).
ESMO Guidelines Committee
Ann Oncol; 2017 Jul; 28(suppl_4):iv143-iv144. PubMed ID: 28881922
[No Abstract] [Full Text] [Related]
3. Appendix 2: Medullary Thyroid Cancer: eUpdate published online 19 February 2018 (http://www.esmo.org/Guidelines/Endocrine-and-Neuroendocrine-Cancers/Thyroid-cancer).
ESMO Guidelines Committee
Ann Oncol; 2018 Oct; 29(Suppl 4):iv257-iv258. PubMed ID: 30285217
[No Abstract] [Full Text] [Related]
4. Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis.
Mansourian M; Ghasemi Ms K; Khorsandi PhD D; Vaseghi G
Am J Ther; 2020; 27(5):e541-e543. PubMed ID: 31107252
[No Abstract] [Full Text] [Related]
5. [Androgen deprivation plus abiraterone/prednisone in metastatic hormone-sensitive prostate cancer : Joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
Ohlmann CH; Miller K; Gschwend J
Urologe A; 2017 Sep; 56(9):1185-1186. PubMed ID: 28733874
[No Abstract] [Full Text] [Related]
6. Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
Kretschmer A; Todenhöfer T
Eur Urol Focus; 2019 Mar; 5(2):114-116. PubMed ID: 30482584
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?
Joseph N; Anjanappa M; Choudhury A
Cancer J; 2020; 26(1):83-86. PubMed ID: 31977390
[TBL] [Abstract][Full Text] [Related]
8. Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.
Tierney JF; Vale CL; Parelukar WR; Rydzewska L; Halabi S
Eur Urol Focus; 2019 Mar; 5(2):137-143. PubMed ID: 30713089
[TBL] [Abstract][Full Text] [Related]
9. Combined androgen blockade in prostate cancer: meta-analyses and associated issues.
Klotz L
BJU Int; 2001 Jun; 87(9):806-13. PubMed ID: 11412217
[No Abstract] [Full Text] [Related]
10. Appendix 7: Metastatic non-small-cell lung cancer (1): MCBS eUpdate published online 28 June 2017 (www.esmo.org/Guidelines/Lung-and-Chest-Tumours).
ESMO Guidelines Committee
Ann Oncol; 2017 Jul; 28(suppl_4):iv158-iv161. PubMed ID: 28881928
[No Abstract] [Full Text] [Related]
11. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
Moul JW
Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
[No Abstract] [Full Text] [Related]
12. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
Walczak JR; Carducci MA;
Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
[TBL] [Abstract][Full Text] [Related]
13. NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Jilani A; George E; Adler AI
Lancet Oncol; 2012 Jun; 13(6):573-4. PubMed ID: 22833888
[No Abstract] [Full Text] [Related]
14. NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.
Carroll PH; Mohler JL
J Natl Compr Canc Netw; 2018 May; 16(5S):620-623. PubMed ID: 29784740
[TBL] [Abstract][Full Text] [Related]
15. [Maximal androgen blockade in the treatment of patients with disseminated cancer of the prostate].
Matveev BP; Bukharkin BV
Vopr Onkol; 1998; 44(5):537-40. PubMed ID: 9884710
[TBL] [Abstract][Full Text] [Related]
16. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
Pienta KJ;
Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
[TBL] [Abstract][Full Text] [Related]
17. Treatment of prostate cancer with hormonal therapy in Europe.
Miller K; Anderson J; Abrahamsson PA
BJU Int; 2009 Mar; 103 Suppl 2():2-6. PubMed ID: 19228146
[No Abstract] [Full Text] [Related]
18. A re-assessment of the role of combined androgen blockade for advanced prostate cancer.
Klotz L; Schellhammer P; Carroll K
BJU Int; 2004 Jun; 93(9):1177-82. PubMed ID: 15180600
[No Abstract] [Full Text] [Related]
19. Factors to Guide Treatment Selection for Hormone-Sensitive Metastatic Prostate Cancer.
Tsao PA; Caram MEV
Cancer J; 2020; 26(1):76-82. PubMed ID: 31977389
[TBL] [Abstract][Full Text] [Related]
20. Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org/Guidelines/Gastrointestinal-Cancers).
ESMO Guidelines Committee
Ann Oncol; 2017 Jul; 28(suppl_4):iv157. PubMed ID: 28881927
[No Abstract] [Full Text] [Related]
[Next] [New Search]
